AIM ImmunoTech Inc.
AIM · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.01 | -0.01 |
| FCF Yield | -88.55% | -26.77% | -28.64% | -35.83% |
| EV / EBITDA | -1.86 | -3.44 | -2.91 | -2.18 |
| Quality | ||||
| ROIC | -66.38% | 70.73% | 271.09% | -361.64% |
| Gross Margin | -369.23% | 60.00% | 37.50% | 213.33% |
| Cash Conversion Ratio | 1.55 | 0.55 | 0.64 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.59% | -10.36% | -2.18% | 6.69% |
| Free Cash Flow Growth | -188.91% | 27.27% | 40.67% | -24.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.90 | -0.47 | -0.21 |
| Interest Coverage | -15.98 | -17.76 | -29.19 | -44.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -923.61 | -65,673.00 | -62,389.13 | 11,264.12 |